Stone, Benjamin V.
Labban, Muhieddine
Beatrici, Edoardo
Filipas, Dejan K.
Frego, Nicola
Qian, Zhiyu
Voleti, Sandeep S.
Osman, Nora Y.
Pomerantz, Mark M.
Lipsitz, Stuart R.
Feldman, Adam S.
Kibel, Adam S.
Cole, Alexander P.
Trinh, Quoc-Dien
Article History
Received: 26 June 2023
Accepted: 27 October 2023
First Online: 20 January 2024
Declarations
:
: ASF reports consulting fees from Janssen, Olympus, Urogen, Lantheus, stock options from Vessi Medical and Scentient, and research funding from Convergent Genomics and NIH. ASK reports consulting fees from Profound, Janssen, Merck, Bayer, Cellvax, Candel, Bristle-Meyer Squibb. QDT reports consulting fees from Astellas, Bayer, and Janssen outside the submitted work and research funding from the American Cancer Society and Pfizer Global Medical Grants. APC reports research funding from the American Cancer Society and Pfizer Global Medical Grants. The other co-authors report no conflicts of interest.
: All data used were publicly available and de-identified and deemed exempt by the Brigham and Women’s Hospital Institutional Review Board.